BioSpace News Archive

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its oral Factor D inhibitor, BCX9930, significantly increased hemoglobin and reduced transfusions in an ongoing dose-ranging trial in treatment-naïve (no prior treatment with C5 inhibitors) paroxysmal nocturnal hemoglobinuria (PNH) patients, and in PNH patients with an inadequate response to C5 inhibitors.

Context Therapeutics, a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, today announced the appointment of Richard Berman, Jennifer Evans Stacey and Linda West as independent members to its Board of Directors, and Mr. Berman has been named Chairman

Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced completion of patient recruitment in its Phase 1 clinical trial of DARE-HRT1 being conducted through its wholly owned subsidiary in Australia. DARE-HRT1 is a novel intravaginal ring (IVR) designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period. It is being developed for the treatment of vasomotor s

- Company can file New Drug Application (NDA) for Wakix, a narcolepsy drug approved in the U.S. and Europe, using overseas clinical trial data - - The new alliance with CARD, announced during Sleep Awareness Week 2021, further empowers Citrine to build the first rare disease ecosystem in China -

Protein Metrics’ software solutions complement Thermo Fisher’s mass spectrometry systems to facilitate precise, reliable data processing and drive innovation

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and 12 months ended December 31, 2020 after the market closes on Monday, March 29, 2021.

Following feedback from the U.S. Food and Drug Administration (FDA) in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. (NASDAQ: ODT) has concluded that the clinical data package for tesetaxel is unlikely to support FDA approval. Therefore, Odonate is discontinuing the development of tesetaxel and will wind down the operations of the Company.

Akers Biosciences, Inc (Nasdaq: AKER), today announced that it has scheduled its general meeting of shareholders (the “Meeting”) to vote on the proposed business combination with MyMD Pharmaceuticals (“MyMD”). The meeting will be held on April 15, 2021 at 10:00 a.m., Eastern Time, and will be “virtual,” meaning that you can participate in the meeting online at www.virtualshareholdermeeting.com/AKER202

Novamind Inc., a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the Benzinga Biotech Small Cap Conference, a virtual conference taking place on March 25th, 2021.

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that Bhavesh Ashar has been appointed Chief Commercial Officer.